Single vaccine dose shows 84% effectiveness against mpox, but insufficient for HIV patients

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended. The results of the study have now been published in The Lancet Infectious Diseases.

Diabetes treatment approach replicates pancreatic functions with bioink and 3D bioprinting technology

A research team has successfully developed an innovative platform for diabetes treatment using bioink derived from pancreatic tissue and 3D bioprinting technology. This study was recently published online in Nature Communications. The team was led by Professor Jinah Jang at Pohang University of Science and Technology (POSTECH), along with Myungji Kim, a Ph.D. candidate.

Deep dive: Family caregivers’ journeys navigating alcohol use disorder

Alcohol use disorder (AUD) is a major global public health issue, affecting more than 28 million adults in the United States and causing 3 million deaths each year worldwide. The impact of AUD extends beyond the individual. At least five people are affected by an individual’s drinking problem, with family members typically stepping into the role of primary caregiver.